Radiotherapy for thyroid cancer
External beam radiotherapy is used to treat some types of thyroid cancer. Find out how it works and learn some of the side effects.
Follicular and papillary thyroid cancer
Medullary thyroid cancer
Radiotherapy may be used for people with medullary thyroid cancer who have a high risk of cancer coming back in the neck after surgery. Or if some parts of the cancer could not be removed with surgery, or if it has spread to other parts of the body.
Anaplastic thyroid cancer
External beam radiotherapy does not make you radioactive. It is safe for you to be with other people, including children, throughout your treatment.
Before you start your treatment, it needs to be carefully planned. Planning makes sure that the radiotherapy is aimed precisely at the cancer. This means it causes the least possible damage to the surrounding healthy tissue.
If your neck area is being treated, you will need to have a mould or mask made before your treatment is planned. This is to keep your head still while you have treatment. You will also have a CT scan to help with planning.
Radiotherapy can cause general side effects such as tiredness (fatigue).
Side effects of radiotherapy to the neck can include:
- discomfort or pain when swallowing
- a dry throat, and sometimes mouth
- thick, sticky saliva
- taste changes
- skin changes in the area being treated – the skin may become sore, red or darker than normal.
Your doctor, specialist nurse or radiotherapist will discuss any possible side effects with you before you start your treatment. They can also give you information to help you cope with any side effects.
Support from Macmillan
Macmillan is here to support you. If you would like to talk, you can do the following:
Below is a sample of the sources used in our thyroid cancer information. If you would like more information about the sources we use, please contact us at email@example.com
British Medical Journal. Best Practice Guidelines, Thyroid cancer. 2020.
European Society Medical Oncology (ESMO): Thyroid cancer, Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. 2019.
National Institute for Health and Care Excellence (NICE). TA535: Lenvatinib and Sorafenib for treating differentiated thyroid cancer after radioactive iodine. 2018. www.nice.org.uk/guidance/ta535 [accessed May 2021].
This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer. It has been approved by Senior Medical Editor, Professor Nick Reed, Consultant Clinical Oncologist.
Our cancer information has been awarded the PIF TICK. Created by the Patient Information Forum, this quality mark shows we meet PIF’s 10 criteria for trustworthy health information.
The language we use
We want everyone affected by cancer to feel our information is written for them.
We try to make sure our information is as clear as possible. We use plain English, avoid jargon, explain any medical words, use illustrations to explain text, and make sure important points are highlighted clearly.
We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected. Our aims are for our information to be as clear and relevant as possible for everyone.
You can read more about how we produce our information here.